Evopoint Biosciences Inc.

Quick facts

Marketed products

• Imipenem/Cilastatin/Relebactam · Infectious Disease
  Imipenem/cilastatin/relebactam is a combination of a broad-spectrum beta-lactam antibiotic, a renal dehydropeptidase inhibitor, and a beta-lactamase inhibitor that together kill bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.

Phase 3 pipeline

• XNW5004 placebo; Chidamide · Oncology
  Chidamide is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and the activation of tumor suppressor genes.

Phase 2 pipeline

• XNW5004 tablets

Phase 1 pipeline

• XNW27011
• XNW28012
• XNW29016
• XNW3009
• XNW34017
• XNW4107
• XNW5004
• XNW7201 tablets

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Evopoint Biosciences Inc. portfolio CI brief
• Evopoint Biosciences Inc. pipeline updates RSS